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Abstract: Tinea capitis (TC) is a common dermatophyte infection affecting primarily   prepubertal 
children. The causative pathogens belong to only two genera: Trichophyton and Microsporum. 
Although there is a great local variation in the epidemiology of TC worldwide, T. tonsurans is 
currently the most common cause of TC with M. canis second. Even though there is an emerg-
ing number of anthropophilic scalp infections, M. canis remains the predominant causative 
organism in many countries of the Mediterranean basin, the most important dermatophyte car-
riers being stray cats and dogs as well as pet puppies, kittens and rabbits. TC always requires 
systemic treatment because topical antifungal agents do not penetrate down to the deepest part 
of the hair follicle. Since the late 1950s, griseofulvin has been the gold standard for systemic 
therapy of TC. It is active against dermatophytes and has a long-term safety profile. The main 
disadvantage of griseofulvin is the long duration of treatment required which may lead to reduced 
compliance. The newer oral antifungal agents including terbinafine, itraconazole, ketokonazole, 
and fluconazole appear to have efficacy rates and potential adverse effects similar to those of 
griseofulvin in children with TC caused by Trichophyton species, while requiring a much shorter 
duration of treatment. They may, however, be more expensive.
Keywords: tinea capitis, children, fungal infection, greseofulvin, terbinafine, itraconazole, 
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Introduction
Tinea capitis (TC) is a dermatophyte infection of the scalp hair follicles and interven-
ing skin.1,2 It affects primarily prepubertal children. The reported prevalence in Europe 
is around 1.5%.
The causative pathogens belong to only two genera: Trichophyton and Microspo-
rum. Although there is a great local variation in the epidemiology of TC worldwide, 
T. tonsurans is currently the most common cause of TC with M. canis the second.
Even though there is an emerging number of anthropophilic scalp infections, 
M. canis remains the predominant causative organism in many countries of the 
  Mediterranean basin, the most important dermatophyte carriers being stray cats and 
dogs as well as pet puppies, kittens and rabbits.
Dermatophyte classification  
and pathogenesis of TC
Dermatophytes are keratinophilic fungi which belong to three genera: Trichophyton, 
Microsporum, and Epidermophyton. On the basis of host preference and natural habitat, 
dermatophytes are classified as anthropophilic, zoophilic, and geophilic.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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TC is mainly caused by anthropophilic and zoophilic 
species of the genera Trichophyton and Microsporum.1,2
On the basis of the type of hair invasion, dermatophytes 
are also classified as endothrix, ectothrix or favus.
In endothrix infection the fungus grows completely within 
the hair shaft, the hyphae are converted to arthroconidia 
(spores) within the hair while the cuticle surface of the hair 
remains intact.
In ectothrix infection hair invasion develops in a man-
ner similar to endothrix except that the hyphae destroy the 
hair cuticle and grow around the exterior of the hair shaft. 
Arthroconidia may develop both within and outside the hair 
shaft. Elongated hyphae, parallel to the long axis of the hair, 
persist within the hair.
Favus is characterized by production of hyphae, which are 
parallel to the long axis of the hair shaft. When the hyphae 
degenerate, long tunnels are left within the hair shaft.1,2
Ectothrix anthropophilic infections potentially spread 
rapidly whereas endothrix and favic infections are less 
contagious.3
Epidemiology
TC is a common dermatophyte infection affecting primarily 
prepubertal children. Adults are infrequently affected.2,4,5 
The reported prevalence in Europe ranges between 0.23% 
and 2.6%.6,7
The causative pathogens belong to only two genera: 
Trichophyton and Microsporum. Although there is a great 
local variation in the epidemiology of TC worldwide, 
T. Tonsurans is currently the most common cause of TC and 
M. Canis the second one (Table 1).8
Even though there is an emerging number of anthropo-
philic scalp infections, M. canis remains the predominant 
causative organism in many countries of the Mediterranean 
basin, being stray cats and dogs as well as pet puppies, kittens 
and rabbits the most important dermatophyte carriers.8
On the other hand, anthropophilic TC has been mainly 
reported in children of Afro-Caribbean descent living in 
urban areas. These dermatophytosis are most frequently 
incurred by contact with an infected child, either directly 
or via fomites.8,9 It has been recently reported that an 
  asymptomatic adult carrier may provide a source for contin-
ued reinfection in children.
T. schoenleinii causes a chronic form of TC that is usu-
ally acquired before adolescence and extending into adult-
hood. Fortunately, it has nearly disappeared from developed 
countries.10
Clinical presentation
Four clinical infection patterns have been reported. Different 
clinical presentation may arise depending on the causative 
organism, the type of hair invasion, and the specific host 
T-lymphocyte inflammatory response.4
Noninflammatory black dot pattern is clinically char-
acterized by well-demarcated areas of hair loss. Fungal 
arthrospores proliferate inside the hair shafts, weakening 
them. Hairs break off at or below the scalp surface, giving the 
characteristic appearance of black dots on the alopecic patch. 
Cell-mediated immunity to fungal antigen skin test is usually 
negative and adenopathy is often absent. (Figure 1).
Noninflammatory seborrheic dermatitis type is a diffuse 
or patchy, fine, white, adherent scale affecting the scalp. 
This is the most difficult to diagnose because it resembles 
dandruff and only one third of patients have a positive potas-
sium hydroxide examination.
In inflammatory tinea capitis (Kerion), there are one or 
multiple tender, inflamed, alopecic nodules with pustules on 
their surface. Fever, occipital adenopathy, leukocytosis, and 
even a diffuse, morbilliform rash may occur. Most patients 
have a positive skin test to fungal antigen, suggesting that 
the patient’s immune response may account for the intense 
inflammation.
Table 1 worldwide etiological agents causing TC
Species Types
Trichophyton tonsurans Anthropophilic
Microsporum canis Zoophilic
Microsporum audouinii Anthropophilic
Trichophyton soudanense Anthropophilic
Trichophyton violaceum Anthropophilic
Figure 1 Tinea capitis endotrix.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Favus is a rare type of inflammatory TC characterized by 
typical honey-colored, cup-shaped, follicular crusts called 
scutula. Kerion Celsi and favus have the potential to cause 
scarring and permanent alopecia (Figure 2).2,3,11
A dermatophytid (id) reaction may accompany oral anti-
fungal therapy and does not represent a widespread fungal 
infection. It is clinically characterized by a pruritic, papular 
or vesicular eruption that typically begins on the face and 
then spreads to the trunk. It is a reactive phenomenon that 
may be the result of a cell-mediated immune response to 
the dermatophyte, triggered by the antimycotic treatment. 
Topical steroids may be required to control the symptoms, 
but it is usually not necessary to discontinue oral antifungal 
treatment. Dermatophytid (id) reaction can also manifest as 
erythema nodosum.2
Differential diagnosis
Seborrheic dermatitis, atopic dermatitis, pseudotinea 
amiantacea and psoriasis may be confused with the dif-
fuse noninflammatory form of TC. The black dot alopecia 
patterns should be differentiated from alopecia areata and 
trichotillomania whereas the inflammatory forms should be 
distinguished from bacterial infections or tumours.2,3,11 Tinea 
versicolor is usually very easy to differentiate.
Asymptomatic dermatophyte  
scalp carriage
The asymptomatic carrier state refers to a clinical situation 
where a person shows no signs or symptoms of TC, yet a 
dermatophyte positive scalp culture is obtained. Although the 
asymptomatic carriage typically occurs in adults who have 
been exposed to children, it may also affect children. Asymp-
tomatic carriers at home or at school shed the fungus and 
are potentially important sources of disease transmission.2,3 
Consequently, some experts advocate treating all carriers 
with antimycotic drugs.
The aymptomatic carriage seems to be restricted 
to anthropophilic dermatophytes such as T. tonsurans, 
T. violaceum, and M. audouinii. These organisms generally 
lack host inflammatory response and consequently mild 
signs of infection escape clinical detection. On the other 
hand, zoophilic dermatophytes such as M. canis or 
T. mentagrophytes usually produce severe signs of infection 
and are, therefore, unlikely to lead to an asymptomatic 
carrier state.
Laboratory diagnosis
The laboratory diagnosis of scalp tinea is made by first 
examining scale and hair on a microscope slide in a potas-
sium hydroxide wet mount and then culturing hair and scalp 
scale. Wood’s light examination is of little value nowadays 
because in western countries most infections are due to 
T. tonsurans, which does not fluoresce.
Specimen collection
The specimen should be collected by experienced staff, in a 
sufficient amount, from the edge of the infected area, which 
corresponds to the active zone of the lesion.
Any crusts should be carefully removed with tweezers 
and the lesion should be disinfected with 70% alcohol before 
sampling, to remove contaminants such as bacteria. Due to 
electrostatic attraction, plastic boxes are unsuitable, so speci-
mens have to be collected in sterile glass containers.12,13
Toothbrush culture sampling is largely of value for scaly 
lesions and consists of rubbing a sterilized toothbrush over 
the suspected areas.
For sampling an alopecic area with short hairs the most 
effective method is to rub the area firmly with a water-
moistened tightly-woven gauze. Afterwards, each hair is 
lifted off the gauze with a needle or forceps and placed on a 
slide for potassium hydroxide preparation.
Human or animal asymptomatic carriers may be detected 
by rubbing the whole scalp or hair with a sterile piece of 
carpet, a sterile swab moistened with distilled water, or a 
hairbrush. The brush or carpet square are especially useful 
methods for suspected asymptomatic carrier cats or other 
pets. The brush or carpet square is combed through the coat,  Figure 2 Kerion celsi.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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trapping fungal spores with hair and debris, and then pressed 
onto the surface of the culture medium.13
Microscopic examination
Direct microscopic examination of skin scrapings and hair 
is the most rapid method of establishing fungal etiology. 
Although it has been reported to have 5%–15% false-
negative results in routine practice, depending on the skill 
of the observer and on the quality of sampling, microscopic 
examination is essential, as it may allow the clinician to start 
treatment, pending culture results.13,14
Hair roots and skin scrapings are mounted in 10%–20% 
potassium hydroxide solution with or without dimethyl sul-
foxide (DMSO). The slide is gently heated and microscopi-
cally examined for hyphae and spores. (Figure 3).
Other dissociating agents have also been proposed includ-
ing Amann’s chloral-lactophenol, which allows clearing 
without heating.
Congo red (a b-D-glucans stain) or Calcofluor white 
0.1% solution (a chitin binding fluorochrome dye) added 
to the clearing reagent facilitate the visualization of fun-
gal structures, but the latter requires use of a fluorescence 
microscope.13
The appearance of infected hairs depends on the invading 
dermatophyte species (Table 2). Hyphae must be differenti-
ated from fibers of cotton wool or synthetic fabrics and from 
‘mosaic’ which is a network of debris including cholesterol 
crystals around epidermal cells.
Culture
Plucked hair fragments and skin scrapings are placed directly 
on a culture medium. The brush-culture method involves 
gently rubbing a previously sterilized toothbrush in a circular 
motion over areas where scale is present, or over the margins 
of patches of alopecia. The brush fibers are then pressed into 
the culture media and the brush discarded. A cotton swab 
produces similar results. Cultures turn positive when using 
these collection techniques.
The two most common media are Sabouraud’s agar 
and Mycobiotic agar containing chloramphenicol and 
cycloheximide to suppress the growth of bacterial sapro-
phytic contamination. Dermatophyte test medium (DTM) 
is similar to Mycobiotic agar but contains a color indicator 
that changes from yellow to red in the presence of dermato-
phyte fungi.
Cultures are usually incubated at 20–30°C for 3–4 weeks 
(or for up to 6 weeks if T. verrucosum, T. violaceum 
(Figure 4) or T. soudanense are suspected) and macro-
scopically screened at least twice a week for signs of fungal 
growth. Cultures usually show signs of growth in 7–10 days. 
Fungal identification is based on macroscopic (growth 
characteristics, pigment formation) as well as microscopic 
morphology (formation of macroconidia and microconidia 
or other typical elements). Additionally, in case of atypi-
cal isolates, some biochemical or physiological tests may 
be performed such as the search for urease activity or the 
in vitro hair perforation test.13
Figure 3 Optical examination of the infected hair shaft. Tinea capitis ectotrix.
Table 2 Hair invasion of dermatophytes
Site Dermatophyte
ectothrix M. audouinii
M. canis
M. ferrugineum
T. mentagrophytes
T. verrucosum
endothrix T. tonsurans
T. violaceum
T. soudanense
Favic T. Schoenlenii
Figure 4 T. Violaceum shows a highly characteristic aspect.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Numerous methods for rapid nucleic acid-based 
  distinction of dermatophyte species have also been described 
in recent years but are not routinely performed in clinical 
practice.15–17
wood’s light examination
The utility of Wood’s ultraviolet light examination depends 
on whether the dermatophyte is an ectothrix or endothrix. 
When ectothrix dermatophytes such as M. canis, M. audouinii 
and M. distortum are examined under a Wood’s lamp the hair 
shows a bright yellow-green fluorescence.18
Wood’s light examination may, therefore, be a useful 
diagnostic aid for school screening surveys in ecthotrix 
anthropohilic cases.
On the other hand, endothrix dermatophytes like 
T.   tonsurans and T. violaceum do not fluoresce at all and 
the use of Wood’s light for screening and monitoring TC 
infection is limited.
Treatment
TC always requires systemic treatment because topical 
antifungal agents do not penetrate down to the hair follicle 
root. Topical treatment is only used as adjuvant therapy to 
systemic antifungals.
Factors that may influence the choice between equally 
effective therapies include tolerability, safety, compliance, 
availability of liquid formulation and cost.
Since the late 1950s, griseofulvin has been the gold 
standard for systemic therapy of TC. It is active against 
dermatophytes and has a long-term safety profile. The main 
disadvantage of griseofulvin is the long duration of treatment 
required (6–12 weeks or longer) which may lead to reduced 
compliance.19
The newer oral antifungal agents including terbinafine, 
itraconazole, ketokonazole, and fluconazole appear to have 
efficacy rates and potential adverse effects similar to those 
of griseofulvin in children with TC caused by Trichophyton 
species, while requiring a much shorter duration of treatment. 
They may, however, be more expensive.20 Consequently, the 
treatment decision between griseofulvin and newer antifungal 
agents for children with Trichophyton spp. tinea capitis can be 
based, for an individual patient, on the balance between dura-
tion of treatment/compliance and economic considerations. 
However terbinafin is preferably used to treat T. tonsurans 
tinea capitis in children, but it is not effective enough in 
the treatment of M. canis tinea capitis. On the other hand, 
fluconazole is more effective in the treatment of M. canis 
compared to terbinafine.
Conversely, griseofulvin is still the treatment of choice for 
cases caused by Microsporum species. Its efficacy is superior 
to that of terbinafine,21 and although its efficacy and treat-
ment duration is matched by fluconazole22 and itraconazole23 
griseofulvin is cheaper. It must be noted, however, that 
griseofulvin is nowadays not available in certain countries 
such as Belgium, Greece, Portugal, and Turkey.
Pending culture results, the choice of initial treat-
ment should be based on the patient’s history (eg, ethnic 
origin, contact with animals, practice of some particular 
sports), clinical presentation (eg, the black dot pattern of 
tinea capitis is commonly caused by T. tonsurans), direct 
microscopy (endothrix or ectothrix hair invasion) and 
compliance/cost.
It must be noted that country-specific prescribing infor-
mation, and formula availability of any antifungal should be 
considered prior to prescription.
Oral agents
Griseofulvin
Griseofulvin is fungistatic and inhibits the mitosis of 
dermatophytes by interacting with microtubules and dis-
rupting the mitotic spindle; therefore it works best on 
actively-growing dermatophytes. It is fungistatic against 
Trichophyton, Microsporum and Epidermophyton. It is not 
active against yeasts (including Malassezia), dimorphic fungi 
causing deep infections, Cryptococcus or the fungi causing 
chromomycosis.
Griseofulvin has been available for more than 40 years 
and has proven to be safe. Two types of preparation are avail-
able: microsize and ultramicrosize, either in tablets or in oral 
suspension. The pediatric dose authorized for treating TC is 
15–25 mg/kg/day using the microsize formulation. When 
the ultramicrosize formulation is used a dose of 10–15 mg 
is recommended because it is better-absorbed than the 
microzise form.24 Griseofulvin produces a sustained blood 
level so it should be given in a single or in divided doses 
daily. Absorption varies from person to person: individual 
patients attain consistently high or low levels of drug. Taking 
the drug with fatty meals (eg, creamy yoghurt, chocolate or 
whole milk) may enhance absorption. The recommended 
duration of therapy for TC is 6–12 weeks or until the patient 
tests negative for fungi (light microscopy and culture).23,24 
This long duration of treatment required with griseofulvin is 
a significant disadvantage and leads to noncompliance. As 
is the case with all systemic antifungals longer duration of 
treatment and a higher dose of griseofulvin is needed for ecto-
thrix (eg, M. canis) than endothrix (eg, Trichophyton spp.) Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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infections. Mycological cure and efficacy rates are generally 
high, being in the range of 80%–96%.25
Treatment failures can be observed due to poor compli-
ance, fungal resistance, drug interactions, or side effects.
Griseofulvin is a safe drug. Headaches and gastroin-
testinal disturbances are the most common side effects. 
The dosage can be temporarily lowered to see if symptoms 
clear, but sometimes the drug must be discontinued. Severe 
allergic reactions, hepatic toxicity and leucopenia rarely 
occur; therefore routine blood studies are not necessary 
unless treatment is to last for many months or the dosage is 
exceptionally high (Table 3).
It is contraindicated in children with porphyria, lupus 
erythematosus, or severe liver disease.26
Drug interactions can occur with warfarin, phenobarbital 
and cyclosporine since griseofulvin is a potent inducer of 
microsomal cytochrome P-450 enzymes.24,25 The main disad-
vantage of griseofulvin is the long duration of treatment.25–28
Terbinafine
Terbinafine belongs to the allyamine class of drugs, a new 
generation of antifungal agents. It is fungicidal to dermato-
phytes since it inhibits squalene epoxidase, a membrane-
bound enzyme in the biosynthetic pathway of sterol synthesis 
of the fungal cell membrane. It is well absorbed and binds 
strongly and nonspecifically to plasma proteins.
The absorption characteristics are not altered when 
  terbinafine is taken with food. Its clearance in children is 40% 
higher than in adults. Since terbinafine is highly lipophilic 
and keratophilic, it is distributed throughout adipose tissue, 
dermis, epidermis, nails, and hair and persists in these tissues 
for weeks. Persistence of the drug in plasma is of concern 
when side effects are experienced. Terbinafine is delivered 
to the stratum corneum via the sebum and, to a lesser extent, 
through incorporation into the basal keratinocytes and dif-
fusion through the dermis-epidermis. Terbinafine is not 
found in eccrine sweat. It remains in skin at concentrations 
above the mean inhibitory concentration (MIC) for most 
dermatophytes for 2 to 3 weeks after discontinuation of 
long-term oral therapy. After 6 and 12 weeks of oral therapy, 
terbinafine has been detected in the nail plate for 30 and 
36 weeks, respectively, at a concentration well above the 
MIC for most dermatophytes. Terbinafine is metabolized in 
the liver, and dose adjustments may be needed in patients 
with liver or renal dysfunction.
It is available as 250 mg tablets. The standard pediatric 
single daily dose is 62.5 mg (10–20 kg); 125 mg (20–40 kg) 
and 250 mg ($40 kg). Some suggest a weight-based dose 
of 4 to 5 mg/kg per day as an alternative.29 Terbinafine is 
concentrated in the hair and may remain present at fungicidal 
concentrations for several weeks after a course of treatment 
has been completed.30 The duration of treatment is generally 
4 weeks, although shorter durations (2 weeks) have also been 
reported to be effective.28,31,32
Higher dosages (10–25 kg: 125 mg/day; .25 kg: 
250 mg/day or 12.5 mg/kg/day) or longer duration of treatment 
(8–12 weeks) may be required for M. canis infection.33–36
Side effects of terbinafine are rare and include gastrointes-
tinal symptoms, rashes and headache. Liver enzyme abnor-
malities and drug reactions are occasionally seen. Plasma 
concentrations are reduced by rifampicin and increased by 
cimetidine.30
Itraconazole
Itraconazole is a triazole antifungal agent against Trichophy-
ton and Microsporum spp. It exhibits both fungistatic and 
fungicidal activity depending on its concentration in the 
tissues, though its primary mode of action is fungistatic 
by inhibiting the cytochrome P-450-dependent enzymes, 
blocking the synthesis of ergosterol, the principal compo-
nent of fungal cell membranes. Itraconazole is lipophilic 
and has a high affinity for keratinizing tissues. It adheres to 
the lipophilic cytoplasm of keratinocytes in the nail plate, 
allowing progressive buildup and persistence in the nail 
Table 3 Dosing pediatric regimens for the treatment of tinea 
capitis
Antifungal  
agent
Dosage Duration of  
treatment
Griseofulvin 
  Microsize 
  Ultramicrosize
20–25 mg/kg/day 
10–15 mg/kg/day
6–12 weeks or 
longer until fungal 
cultures are 
negative
Terbinafine 10–20 kg: 62.5 mg/day 
20–40 kg: 125 mg/day 
.40 kg: 250 mg/day 
Or  
4–5 mg/kg/day
Trichophyton 
spp.: 2–4 weeks 
Microsporum spp.: 
8–12 weeks
Itraconazole Capsules: 5 mg/kg/day 
Oral solution: 3 mg/kg/day
Daily dosing:  
2–6 weeks  
Pulse regimen  
(1 week with 2 weeks 
off between the first 
2 pulses and  
3 weeks between the 
2nd and 3rd): 2–3 
pulses (range: 1–5)
Fluconazole Daily dosing: 5–6 mg/kg/day 
weekly dosing: 8 mg/kg 
once weekly
3–6 weeks  
8–12 weeksClinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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plate. The drug reaches high levels in the nails that persist 
for at least 6 months after discontinuation of 3 months of 
therapy and during pulsed cycles. The concentration in the 
stratum corneum remains detectable for 4 weeks after therapy. 
Itraconazole levels in sebum are 5 times higher than those in 
plasma and remain high for as long as 1 week after therapy. 
This fact suggests that secretion in sebum may account for 
the high concentrations found in skin. The drug has an affinity 
for mammalian cytochrome P-450 enzymes, as well as for 
fungal P-450-dependent enzyme, and thus has the potential 
for clinically-important interactions with astemizole, rifam-
picin, oral contraceptives, H2 receptor antagonists, warfarin 
and cyclosporine.
It is available as capsules or an oral solution. Itracon-
azole capsule formulation should be ingested with a meal 
whereas the oral solution should be taken in the fasting state 
for optimum bioavailability. The response to therapy does 
not appear to depend upon the formulation administered 
(capsules versus suspension).
The recommended pediatric dose is 5 mg/kg/day given 
continuously or by repeat pulsing. Where the oral solution 
is used, dosage is reduced to 3 mg/kg/day.37
Using the continuous regimen, the duration of treat-
ment for Trichophyton spp.38 and Microsporum spp. tinea 
capitis39 is 2 and 6 weeks with cure rates of 85.7% and 88% 
respectively. It must be noted that the 6-week regimen of 
itraconazole is of comparable efficacy to griseofulvin, in 
cases of Microsporum-TC.19
In the pulse regimen (one pulse of 5 mg/kg/day for 1 week 
with 2 weeks off between the first two pulses and 3 weeks 
between the second and third), the number of pulses required 
for the treatment depends in part on the severity of the TC.40 
In this way it may be possible to individualize the number of 
pulses administered according to the clinical response.
Side effects of itraconazole include headache, gastro-
intestinal complaints, rash and occasionally liver enzyme 
abnormalities. Less common is peripheral edema especially 
when taken with calcium channel blockers.
Itraconazole may increase plasma concentration of 
cyclosporine, certain benzodiazepines (midazolam, tri-
azolam, alprazolam, and estazolam), digoxin, and cisapride. 
Concomitant use of H2-receptor antagonists, phenytoin, 
isoniazid, and rifampin may reduce the plasma concentration 
of itraconazole. Its use is strongly discouraged for patients 
with elevated or abnormal liver enzymes, active liver disease 
or who have experienced liver toxicity with other antifungal 
azole drugs. It is contraindicated in patients with evidence of 
ventricular dysfunction such as congestive heart failure.
Fluconazole
Fluconazole is primarily a fungistatic triazole, preventing the 
conversion of lanosterol to ergosterol, an essential component 
of the fungal cytoplasmic membrane. It is distinguished from 
the other azoles by its water solubility that results in excellent 
bioavailability by the oral route. Because fluconazole is highly 
soluble in water it is transported to the skin through sweat and 
concentrated by evaporation. It achieves high concentrations 
in the epidermis and nails and persists up to 3 months.41
It is available as a tablet or oral suspension. Doses of 
5–6 mg/kg/ per day for 4–6 weeks can effectively treat TC.22 
Once-weekly 8 mg/kg pulse dosing for 8–12 weeks is an 
alternative regimen.42
Evidence suggest that in respect to Trichophyton species 
TC, a 2–4-week regimen of fluconazole has similar cure rates 
to a 6-week regimen of griseofulvin.20
Two studies that included 140 children found similar 
cure rates of 2–4 weeks of fluconazole when compared with 
6 weeks of griseofulvin (RR 0.92; 95% CI 0.80 to 1.05).
Side effects of fluconazole are similar to other azole 
derivatives. Hematologic and hepatic toxicity may occasion-
ally occur.
Drug interaction: terfenadine, cisapride (risk of serious 
cardiac arrhythmias)
Contraindications: severe liver disease. Use with caution 
in patients sensitive to other azoles.
Topical agents
Adjunctive topical therapies such as Selenium sulphide,43 
zinc pyrithione, povidoneiodide or ketoconazole44 shampoos 
as well as fungicidal creams or lotions45 have been shown 
to decrease the carriage of viable spores responsible for 
the disease contagion and reinfection and may shorten the 
cure rate with oral antifungal. A terbinafine solution 0.01% 
completely killed arthroconidia of five Trichophyton species 
after an exposure time of 15–30 min.46
The topical fungicidal cream/lotion should be applied to 
the lesions once daily for a week.45
The shampoo should be applied to the scalp and hair for 
5 minutes twice-weekly for 2–4 weeks39,47 or three times 
weekly until the patient is clinically and mycologically 
cured.19 The authors recommend the latter in conjunction with 
one week of topical fungicidal cream or lotion application.
Additional measures
School attendance
Keeping children out of school after starting therapy is 
controversial. Several experts suggest that once treatment Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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has been initiated with oral and topical agents, the children 
should, for practical reasons, be allowed back to school or day 
care although there is still a risk of infecting fellow students.26 
On the other hand, other experts recommend exemption 
from school/kindergarten attendance, regardless of the type 
of dermatophyte, for approximately 2 weeks after initiation 
of treatment, a period necessary for significant decline of 
infection load in the hair follicle.45
Patient education is, therefore, of utmost importance in 
eradicating TC.
It must be stressed that the degree of disease transmis-
sion depends on the type of the dermatophyte isolated, the 
most contagious being the ectothrix anthropophilic. The 
latter potentially spreads rapidly and often causes epidem-
ics in schools.48 Additionally, topical fungicidal treatment, 
nowadays, can kill arthroconidia rapidly.46
Therefore the following are recommended: If the caus-
ative agent is an anthropophilic ectothrix the child should 
usually be allowed school/kindergarten attendance one week 
after initiation of treatment. Wood’s light is useful to monitor 
the disappearance of contaminating spores. In all other cases 
the child should be allowed to attend school/kindergarten as 
soon as the treatment has been initiated.
When the child is back at school, he/she should be 
strongly advised not to share items such as combs, hair-
brushes, scarves, and hats, as fomites may play a role in 
transmission. School staff may help in enforcing this.
So, in all cases with TC caused by anthropophilic der-
matophytes the school authorities should be notified.48
Sports that lead to prolonged close physical contact (eg, 
wrestling) should be prohibited until the risk of infection no 
longer exists.
Plucking the involved hair, as practiced in many coun-
tries, may help in the rapid resolution of the infection as it 
physically removes large amounts of yeasts.
Sources of infection
Upon positive microscopy and pending culture clinical 
examination of family members is urgently recommended. 
Appropriate mycological samples should be taken initially 
only from those with signs of infection.
Zoophilic organisms such as M. canis cause an inflam-
matory response in nearly all those infected. Conversely, 
anthropophilic organisms, usually either T. tonsurans or 
T. violaceum cause a mild or noninflammatory response, thus 
making them good candidates for asymptomatic carriage.2 
Subsequently, if an anthropophilic organism is finally identi-
fied by culture in the index case, then appropriate quantitative 
culturing should be performed on all family members/close 
contacts even in the absence of clinical signs (brush method). 
‘Close contacts’ include playmates in close physical contact, 
and additionally, in very young children (kindergarten through 
second grade) their schoolmates, since these children are more 
susceptible and have a greater risk of disease transmission.
It remains unclear whether carriers should be treated with 
topical antifungal shampoos or oral antifungal, with both, 
or with neither. In those with moderate or heavy growth of 
culture, oral therapy may be justified as these individuals are 
particularly likely to develop an overt clinical infection; they 
are a reservoir of transmission, and are unlikely to respond 
to topical treatment alone.
For those with low spore counts on culture, twice-weekly 
selenium sulfide or 2% ketoconazole shampoo for up to 
12 weeks is probably adequate.3
Pets (eg, dogs, cats, guinea pigs, hamsters) should also 
be examined and treated as necessary.
It must be noted, however, that stray cats or dogs fre-
quently infect children living in developing countries.
Viable fungal spores have been isolated from the floor, 
backs of chairs, clothing, beds, pillows, curtains, brushes, 
combs, scissors, and other shared facilities in the household. 
Consequently the washable items (eg, bedding and textiles) 
should be laundered, carpets should be vacuum-cleaned, and 
floors mopped with a strong disinfectant. Brushes and combs 
as well as other hair accessories should be disinfected after 
use or discarded.3 The 2007 German-Speaking Mycological 
Society Guideline on TC noted that for items that can be 
boiled, eg, combs or possibly hairbrushes, 5 min in boiling 
water is sufficient. Scissors may be placed in an instrument 
disinfectant eg, 5 min in a Mucocit-B drill bath (this alcohol-
based product is designed for disinfecting dental drills).45
Steroids/antibiotics/antihistamines
Current data indicate that the use of steroids for Kerion 
Celsi may reduce scaling and itching but does not reduce 
the clearance time compared with griseofulvin alone.49,50 
Prednisolone may be used as oral treatment at 1 mg/kg per 
day for 7 days though this is not recommended as part of 
routine care for kerion.51
Also, there are no studies that support the routine use of 
antibiotics in patients with kerion because kerion Celsi is 
rarely subject to secondary bacterial infection.52 Incision or 
excision of kerion nodules is not recommended.53
In patients with pruritus, systemic antihistamines can 
reduce discomfort and may prevent distribution of spores 
via finger scratching.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Follow-up
Clinical and mycological examinations of affected children 
should be conducted at regular intervals (2–4 weeks). The 
treatment may be stopped after the culture becomes negative 
or when hair regrowth is clinically evident: consequently 
the duration of treatment can be individualized according 
to the response.
The causes of treatment failure include suboptimal 
absorption of the medication, relative insensitivity of the 
organism, reinfection and lack of compliance with the long 
courses of treatment.
If at the end of the standard treatment period fungi can 
still be isolated from the lesional skin, but clinical signs have 
improved, the recommendation is to continue the original 
regimen for another month. If there has been no clinical 
improvement then, the original regimen can again be extended 
for a further month though in these cases it is also reasonable 
to switch to an alternative antifungal. Periodic monitoring of 
hepatic enzymes and complete blood count is recommended 
in children during prolonged therapy with itraconazole or 
terbinafine (.4 and 6 weeks, respectively).19 Additionally 
renal function should be monitored when the child is receiving 
prolonged treatment with griseofulvin or fluconazole.
Complications
Some complications have already been cited in the text but 
we should also consider the possibility of scarring, cicatricial 
alopecia, superinfections by bacteria (impetigo) and changes 
in skin color.
If the treatment is adequate, in general, the prognosis 
is good.
Conclusion
We believe that most studies indicate that there is enough 
evidence to support the use of griseofulvin to treat tinea 
capitis in children, which is caused by T. tonsurans, M. canis, 
T. mentagrophytes, and T. violaceum.
Overall, griseofulvin is considered to be safe in 
children.
Terbinafine, when compared with griseofulvin, produces 
good results in a shorter time of treatment, making participant 
compliance less of a problem.
One potential disadvantage, however, is that terbinafine is 
only available in tablet form. While tablets may be preferred 
by some children (aged five years and older, perhaps), they 
may not allow for dosage individualization.
We believe that although griseofulvin will continue 
to remain the antifungal drug of choice in tinea capitis, 
  terbinafine may constitute an alternative drug which is well 
tolerated and has few side effects. It would be interesting 
to see more comparisons between the newer and r  elatively 
expensive antifungals for tinea capitis in children. There 
are currently a limited number of trials involving differ-
ent doses, and further information is needed on treat-
ment doses and frequency for all antifungals including 
griseofulvin.
Acknowledgments
Images 1 to 4 are courtesy of Dr M Lecha and Dr V Lecha.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Gupta AK, Summerbell RC. Tinea capitis. Med Mycol. 2000; 
38:255–287.
  2.  Elewski B. Tinea capitis: a current perspective. J Am Acad Dermatol. 
2000;42:1–20.
  3.  Ilkit M, Demirhindi H. Asymptomatic dermatophyte scalp carriage: 
laboratory diagnosis, epidemiology and management. Mycopathologia. 
2008;165:61–71.
  4.  Razzaq Adel AA, Sultan AO, Basmiah AM, Aftab A, Nabel N. Prevalence 
of tinea capitis in southern Kuwait. Mycoses. 2007;50:317–320.
  5.  Romano C, Gianni C, Papini M. Tinea capitis in infants less than 1 year 
of age. Pediatr Dermatol. 2001;18:465–468.
  6.  Trivino-Duran L, Torres-Rondriguez JM, Martinez-Roig A, et al. 
Prevalence of tinea capitis and tinea pedis in Barcelona schoolchildren. 
Pediatr Infect Dis J. 2005;24:137–141.
  7.  Hay RJ, Clayton YM, De Silva N, Midgley G, Rossor E. Tinea capitis 
in south-east London: a new pattern of infection with public health 
implications. Br J Dermatol. 1996;135:955–958.
  8.  Hay RJ, Robles W, Midgley G, Moore MK. European Confederation 
of Medical Mycology Working Party on Tinea Capitis. Tinea capitis 
in Europe: new perspective on an old problem. J Eur Acad Dermatol 
Venereol. 2001;15:229–233.
  9.  Ginter-Hanselmayer G, Weger W, Ilkit M, Smolle J. Epidemiology of 
tinea capitis in Europe: current state and changing patterns. Mycoses. 
2007;50 Suppl 2:6–13.
  10.  Niczyporuk W, Krajewska-Kuzak E, Zukaszuk C. Tinea capitis favosa 
in Poland. Mycoses. 2004;47:257–260.
  11.  Fuller LC, Child FJ, Midgley G, Higgins EM. Diagnosis and manage-
ment of scalp ringworm. BMJ. 2003;326:539–541.
  12.  Boralevi F, Léauté-Labrèze C, Roul S, Couprie B, Taïeb A. Lupus-
erythematosus-like eruption induced by Trichophyton mentagrophytes 
infection. Dermatology. 2003;206:303–306.
  13.  Robert R, Pihet M. Conventional methods for the diagnosis of dermato-
phytes. Mycopathologia. 2008;166:295–306.
  14.  Panasiti V , Borroni RG, Devirgiliis V , et al. Comparison of diagnostic 
methods in the diagnosis of dermatomycoses and onychomycoses. 
Mycoses. 2006;49:26–29.
  15.  Liu D, Coloe S, Baird R, Pedersen J. Application of PCR to the iden-
tification of dermatophyte fungi. J Med Microbiol. 2000;49:493–497.
  16.  Kac G. Molecular approaches to the study of dermatophytes. Med 
Mycol. 2000;38:329–336.
  17.  Kanbe T, Suzuki Y, Kamiya A, et al. Species identification of dermato-
phytes Trichophyton, Microsporum and Epidermophyton by PCR and 
PCR-RFLP targeting of the DNA topoisomerase II genes. J Dermatol 
Sci. 2003;33:41–54.Clinical, Cosmetic and Investigational Dermatology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal
Clinical, Cosmetic and Investigational Dermatology is an interna-
tional, peer-reviewed, open access, online journal that focuses on 
the latest clinical and experimental research in all aspects of skin 
disease and cosmetic interventions. All areas of dermatology will 
be covered; contributions will be welcomed from all clinicians and 
basic science researchers globally. This journal is indexed on CAS. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
98
Bennassar and Grimalt
  18.  Kefalidou S, Odia S, Gruseck E, Schmidt T, Ring J, Abeck D. 
Wood’s light in Microsporum canis positive patients. Mycoses. 
1997;40:461–463.
  19.  Elewski BE. Treatment of tinea capitis: beyond griseofulvin. J Am Acad 
Dermatol. 1999;40(6 Pt 2):S27–S30.
  20.  Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C. 
Systemic antifungal therapy for tinea capitis in children. Cochrane 
Database Sys Rev. 2007;17:CD004685.
  21.  Elewski BE, Cáceres HW, DeLeon L, et al. Terbinafine hydrochloride 
oral granules versus griseofulvin suspension in children with tinea 
capitis: results of two randomized, investigator-blinded, multicenter, 
international, controlled trials. J Am Acad Dermatol. 2008;59:41–54.
  22.  Foster KW, Friedlander SF, Panzer H. A randomized controlled trial 
assessing the efficacy of fluconazole in treatment of pediatric tinea 
capitis. J Am Acad Dermatol. 2005;53:798–809.
  23.  López-Gómez S, Del Palacio A, Van Cutsem J, Soledad Cuétara M, 
Iglesias L, Rodriguez-Noriega A. Itraconazole versus griseofulvin in the 
treatment of tinea capitis: a double-blind randomized study in children. 
Int J Dermatol. 1994;33:743–747.
  24.  Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr 
Ann. 2005;34:191–200.
  25.  Bennett ML, Fleisher AB, Loveless JW, Feldman SR. Oral griseofulvin 
remains the treatment of choice for tinea capitis in children. Pediatr 
Dermatol. 2000;17:304–309.
  26.  Higgins EM, Fuller LC, Smith CH. Guidelines for the management of 
tinea capitis. British Association of Dermatologists. Br J Dermatol. 
2000;143:53–58.
  27.  Gupta AK, Cooper EA, Bowen JE. Meta-analysis: griseofulvin efficacy 
in the treatment of tinea capitis. J Drugs Dermatol. 2008;7:369–372.
  28.  Gupta KA, Adam P, Dlova N, et al. Therapeutic options for the treatment 
of tinea capitis caused by trychophyton species: Griseofulvin versus the 
new oral antifungal agants, terbinafine, itraconazole and fluconazole. 
Pediatr Dermatol. 2001;18:433–438.
  29.  Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbi-
nafine in children. J Eur Acad Dermatol Venereol. 2003;17:627–640.
  30.  Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine 
in children. Dermatol Clinics. 2003;21:511–520.
  31.  Friedlander SF, Aly R, Krafchik B, et al. A randomized, double-
blind, parallel group duration-finding study of oral terbinafine in 
children with tinea capitis due to Trichophyton species. Pediatr. 
2002;109:602–607.
  32.  Haroon TS, Hussain I, Aman S, et al. A randomized double-blind 
comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. 
Br J Dermatol. 1996;135:86–88.
  33.  Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-
blind, parallel-group, duration-finding study of oral terbinafine and 
open-label, high-dose griseofulvin in children with tinea capitis due to 
Microsporum species. Br J Dermatol. 2002;146:816–823.
  34.  Koumantaki E, Kakourou T, Rallis E, Riga P, Georgalla S. Doubled 
dose of oral terbinafine is required for Microsporum canis tinea capitis. 
Pediatr Dermatol. 2001;4:339–342.
  35.  Friedlander SF, Aly R, Krafchik B, et al. Terbinafine in the treatment of 
Trichophyton tinea capitis: a randomized, double-blind, parallel-group, 
duration-finding study. Pediatr. 2002;109:602–607.
  36.  Devliotou-Panagiotidou D, Koussidou-Eremondi TH. Efficacy and 
tolerability of 8 weeks’ treatment with terbinafine in children with tinea 
capitis caused by Microsporum canis: a comparison of three doses. 
J Eur Acad Dermatol Venereol. 2004;18:155–159.
  37.  Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the 
treatment of tinea capitis. Br J Dermatol. 1998;139:104–106.
  38.  Jahangir M, Hussain I, Ul Hasan M, Haroon TS. A double-blind, 
randomized, comparative trial of itraconazole versus terbinafine for 
2 weeks in tinea capitis. Br J Dermatol. 1998;139:672–674.
  39.  Ginter-Henselmayer G, Smolle J, Gupta A. Itraconazole in the treatment 
of tinea capitis caused by Microsporum canis: Experience in a large 
cohort. Pediatr Dermatol. 2004;21:499–502.
  40.  Gupta AK, Hofstader SL, Summerbell RC, et al. Treatment of tinea 
capitis with itraconazole capsule pulse therapy. J Am Acad Dermatol. 
1998;39(2 Pt 1):216–219.
  41.  Dastghaib L, Azizzadeh M, Jafari P. Therapeutic options for the treat-
ment of tinea capitis: Griseofulvin versus fluconazole. J Dermatol Treat. 
2005;16:43–46.
  42.  Gupta AK, Dlova N, Taborda P, et al. Once-weekly fluconazole is 
effective in children in the treatment of tinea capitis: a prospective, 
multicentre study. Br J Dermatol. 2000;142:965–968.
  43.  Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: 
adjunctive therapy for tinea capitis. Pediatrics. 1982;69:81–83.
  44.  Greer DL. Successful treatment of tinea capitis with 2% ketoconazole 
shampoo. Int J Dermatol. 2000;39:302–304.
  45.  Seebacher C, Abeck D, Brasch J, et al. Tinea capitis: ringworm of the 
scalp. Mycoses. 2007;50:218–226.
  46.  Gupta AK, Ahmad I, Summerbell RC. Comparative efficacies of com-
monly used disinfectants and antifungal pharmaceutical spray prepara-
tions against dermatophytic fungi. Med Mycol. 2001;39:321–328.
  47.  Fuller LC, Smith CH, Cerio R, et al. A randomised comparison of 
four weeks of terbinafine versus eight weeks of griseofulvin for the 
treatment of tinea capitis – advantages of a shorter treatment schedule. 
Br J Dermatol. 2001;144:321–327.
  48.  Weill FX, Bernier V , Maleville J, et al. Epidémie de teignes du cuir 
chevelu à microsporum audouinii var. langeronii dans un groupe 
scholaire. Bordelais J Mycol Méd. 1999;9:52–56.
  49.  Honig PJ, Caputo GL, Leyden JJ, McGinley K, Selbst SM, McGravey AR. 
Treatment of kerions. Pediatr Dermatol. 1994;11:69–71.
  50.  Hussain I, Muzaffar F, Rashid T, Ahmad TJ, Jahangir M, Haroon TS. 
A randomized, comparative trial of treatment of kerion celsi with 
griseofulvin plus oral prednisolone vs griseofulvin alone. Med Mycol. 
1999;37:97–99.
  51.  Ali S, Graham TA, Forgie SE. The assessment and management of 
tinea capitis in children. Pediatr Emerg Care. 2007;23:662–665.
  52.  Thoma-Greber E, Zenker S, Röcken M, Wolff H, Korting HC. Surgical 
treatment of tinea capitis in childhood. Mycoses. 2003;46:351–354.
  53.  von Laer Tschudin L, Laffitte E, Baudraz-Rosselet F, Dushi G, 
Hohlfeld J, de Buys Roessingh AS. Tinea capitis: no incision nor exci-
sion. J Pediatr Surg. 2007;42:E33–E36.